These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 20068082)

  • 1. New insights into checkpoint kinase 1 in the DNA damage response signaling network.
    Dai Y; Grant S
    Clin Cancer Res; 2010 Jan; 16(2):376-83. PubMed ID: 20068082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods to study cancer therapeutic drugs that target cell cycle checkpoints.
    Dai Y; Grant S
    Methods Mol Biol; 2011; 782():257-304. PubMed ID: 21870298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.
    Bucher N; Britten CD
    Br J Cancer; 2008 Feb; 98(3):523-8. PubMed ID: 18231106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA damage checkpoint kinases in cancer.
    Smith HL; Southgate H; Tweddle DA; Curtin NJ
    Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
    Xiao Z; Xue J; Sowin TJ; Zhang H
    Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Smith J; Tho LM; Xu N; Gillespie DA
    Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
    Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
    Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
    Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint kinase 1 in DNA damage response and cell cycle regulation.
    Patil M; Pabla N; Dong Z
    Cell Mol Life Sci; 2013 Nov; 70(21):4009-21. PubMed ID: 23508805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
    Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
    Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.
    Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D
    Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.
    McNeely S; Beckmann R; Bence Lin AK
    Pharmacol Ther; 2014 Apr; 142(1):1-10. PubMed ID: 24140082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chk1 inhibitors for novel cancer treatment.
    Tao ZF; Lin NH
    Anticancer Agents Med Chem; 2006 Jul; 6(4):377-88. PubMed ID: 16842237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
    Zenvirt S; Kravchenko-Balasha N; Levitzki A
    Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses.
    Yan T; Desai AB; Jacobberger JW; Sramkoski RM; Loh T; Kinsella TJ
    Mol Cancer Ther; 2004 Sep; 3(9):1147-57. PubMed ID: 15367709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug discovery targeting Chk1 and Chk2 kinases.
    Zhou BB; Sausville EA
    Prog Cell Cycle Res; 2003; 5():413-21. PubMed ID: 14593735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chk1 is essential for tumor cell viability following activation of the replication checkpoint.
    Cho SH; Toouli CD; Fujii GH; Crain C; Parry D
    Cell Cycle; 2005 Jan; 4(1):131-9. PubMed ID: 15539958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unleashing Chk1 in cancer therapy.
    Carrassa L; Damia G
    Cell Cycle; 2011 Jul; 10(13):2121-8. PubMed ID: 21610326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes.
    Al-Ejeh F; Kumar R; Wiegmans A; Lakhani SR; Brown MP; Khanna KK
    Oncogene; 2010 Nov; 29(46):6085-98. PubMed ID: 20818418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.